Call to ask about our specials 212-447-1155
Ozempic vs. Wegovy vs. Mounjaro for weight loss, the newest GLP-1 agonists are popular medications for treating Type 2 diabetes. But which one is the best for you?
These self-injectable weight loss medications have recently been all over the news, thanks to trending videos shared by celebrities and wellness influencers on social media. They’ve gained notoriety as “miracle” weight loss drugs—but are they?
Can’t decide between Ozempic vs. Wegovy vs. Mounjaro? Just Melt Med Spa has created a comparison chart below for our patients.
How do Wegovy® and Mounjaro® work? Are they safe? And how do they differ from one another? We’re answering those questions and more below.
Wegovy and Ozempic contain the same ingredient, semaglutide. However, Wegovy is approved for weight loss, while Ozempic is approved for type 2 diabetes.
Ozempic, also known as semaglutide, is a prescription drug used to manage type 2 diabetes alongside diet and exercise. The drug, made by pharmaceutical company Novo Nordisk, helps improve blood sugar control and lowers the risk of events like heart attack or stroke.
It is important to note that Ozempic is not used to treat type 1 diabetes, and is not insulin.
In the U.S., the FDA has approved Ozempic for type 2 diabetes and to help prevent serious cardiovascular events such as heart attack or stroke in people with type 2 diabetes and cardiovascular disease.
The ideal candidate for these medications is anyone that needs to lose weight, has diabetes, and needs to have their risk of cardiovascular complications (i.e. heart attack or stroke) reduced.
Ozempic and Wegovy are the same medication (semaglutide) and work the same way, though Wegovy has a higher maximum dose.
Both drugs are manufactured by Novo Nordisk. The major difference is what they are FDA approved for.
While Ozempic is FDA-approved for diabetes, Wegovy has full FDA approval for weight loss. In June 2021, Wegovy was approved for chronic weight management in patients with:
Eli Lilly’s drug Mounjaro is used to help manage type 2 diabetes, diet, and exercise. While its function is the same as the other drugs, it’s slightly different from Ozempic and Wegovy.
Mounjaro is the first of its kind that targets two major hormones that regulate blood sugar levels and can help patients lose weight: GLP-1 and glucose-dependent insulinotropic polypeptide (GIP).
Mounjaro is the newest drug on the market, and it’s in the same class as Ozempic and Wegovy, but with another compound built in to strengthen the effects.
In May 2022, Mounjaro was approved by the FDA for treating type 2 diabetes. While it is not yet approved for weight loss, it might be used off-label for obesity—and soon to be approved for it.
Mounjaro is on the fast-track to be approved for weight loss. The latest clinical trials show Mounjaro was more effective than Ozempic, with patients achieving 26.6% weight loss over 84 weeks.